IDEXX LABORATORIES INC /DE Pre-Tax Income
IDEXX LABORATORIES INC /DE (IDXX) reported Pre-Tax Income of $417.22 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was $417.22M, a 15.14% increase year-over-year.
- IDEXX LABORATORIES INC /DE income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was $355.44M, a 14.63% increase year-over-year.
- IDEXX LABORATORIES INC /DE income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was $306.98M, a 19.73% increase year-over-year.
- IDEXX LABORATORIES INC /DE income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was $344.77M, a 15.34% increase year-over-year.
- IDEXX LABORATORIES INC /DE income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was $1.32B, a 19.31% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was $1.11B, a 4.59% increase from fiscal 2023.
- IDEXX LABORATORIES INC /DE income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was $1.06B, a 23.40% increase from fiscal 2022.
- IDEXX LABORATORIES INC /DE income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was $859.97M, a 4.73% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $417.22M 10-Q · filed 2026-08-04 | $772.67M 10-Q · filed 2026-08-04 | $1.08B derived: sum of 3 quarters · filed 2026-08-04 | $1.42B derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $355.44M 10-Q · filed 2026-05-05 | $662.42M derived: sum of 2 quarters · filed 2026-05-05 | $1.01B derived: sum of 3 quarters · filed 2026-05-05 | $1.37B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $306.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $651.75M derived: sum of 2 quarters · filed 2026-02-20 | $1.01B derived: sum of 3 quarters · filed 2026-08-04 | $1.32B 10-K · filed 2026-02-20 |
| 2025-09-30 | $344.77M 10-Q · filed 2025-11-03 | $707.12M derived: sum of 2 quarters · filed 2026-08-04 | $1.02B 10-Q · filed 2025-11-03 | $1.27B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $362.35M 10-Q · filed 2026-08-04 | $672.44M 10-Q · filed 2026-08-04 | $928.82M derived: sum of 3 quarters · filed 2026-08-04 | $1.23B derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $310.08M 10-Q · filed 2026-05-05 | $566.47M derived: sum of 2 quarters · filed 2026-05-05 | $865.38M derived: sum of 3 quarters · filed 2026-05-05 | $1.12B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $256.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $555.30M derived: sum of 2 quarters · filed 2026-02-20 | $814.35M derived: sum of 3 quarters · filed 2026-02-20 | $1.11B 10-K · filed 2026-02-20 |
| 2024-09-30 | $298.91M 10-Q · filed 2025-11-03 | $557.97M derived: sum of 2 quarters · filed 2025-11-03 | $853.44M 10-Q · filed 2025-11-03 | $1.09B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $259.06M 10-Q · filed 2025-08-04 | $554.53M 10-Q · filed 2025-08-04 | $794.20M derived: sum of 3 quarters · filed 2026-02-20 | $1.06B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $295.48M 10-Q · filed 2025-05-01 | $535.15M derived: sum of 2 quarters · filed 2026-02-20 | $803.04M derived: sum of 3 quarters · filed 2026-02-20 | $1.09B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $239.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $507.56M derived: sum of 2 quarters · filed 2026-02-20 | $793.49M derived: sum of 3 quarters · filed 2026-02-20 | $1.06B 10-K · filed 2026-02-20 |
| 2023-09-30 | $267.89M 10-Q · filed 2024-10-31 | $553.82M derived: sum of 2 quarters · filed 2024-10-31 | $821.51M 10-Q · filed 2024-10-31 | $1.03B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $285.93M 10-Q · filed 2024-08-06 | $553.62M 10-Q · filed 2024-08-06 | $766.83M derived: sum of 3 quarters · filed 2025-02-21 | $1.00B derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $267.69M 10-Q · filed 2024-05-01 | $480.90M derived: sum of 2 quarters · filed 2025-02-21 | $715.09M derived: sum of 3 quarters · filed 2025-02-21 | $886.17M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $213.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $447.40M derived: sum of 2 quarters · filed 2025-02-21 | $618.48M derived: sum of 3 quarters · filed 2025-02-21 | $859.97M 10-K · filed 2025-02-21 |
| 2022-09-30 | $234.18M 10-Q · filed 2023-11-01 | $405.27M derived: sum of 2 quarters · filed 2023-11-01 | $646.76M 10-Q · filed 2023-11-01 | $838.64M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $171.08M 10-Q · filed 2023-08-01 | $412.57M 10-Q · filed 2023-08-01 | $604.46M derived: sum of 3 quarters · filed 2024-02-22 | $823.41M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $241.49M 10-Q · filed 2023-05-02 | $433.37M derived: sum of 2 quarters · filed 2024-02-22 | $652.32M derived: sum of 3 quarters · filed 2024-02-22 | $904.05M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $191.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $410.83M derived: sum of 2 quarters · filed 2024-02-22 | $662.56M derived: sum of 3 quarters · filed 2024-02-22 | $902.65M 10-K · filed 2024-02-22 |
| 2021-09-30 | $218.95M 10-Q · filed 2022-11-01 | $470.68M derived: sum of 2 quarters · filed 2022-11-01 | $710.77M 10-Q · filed 2022-11-01 | $888.21M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-06-30 | $251.73M 10-Q · filed 2022-08-02 | $491.82M 10-Q · filed 2022-08-02 | $669.26M derived: sum of 3 quarters · filed 2023-02-16 | $833.21M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-03-31 | $240.09M 10-Q · filed 2022-05-04 | $417.53M derived: sum of 2 quarters · filed 2023-02-16 | $581.48M derived: sum of 3 quarters · filed 2023-02-16 | |
| 2020-12-31 | $177.44M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $341.39M derived: sum of 2 quarters · filed 2023-02-16 | $661.99M 10-K · filed 2023-02-16 | |
| 2020-09-30 | $163.95M 10-Q · filed 2021-11-02 | $484.55M 10-Q · filed 2021-11-02 | ||
| 2019-12-31 | $522.22M 10-K · filed 2022-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |